Journal of the American Pharmacists Association : JAPhA · 2025
Effects of the prescription drug monitoring program mandate on queries of controlled substance prescriptions: Findings from Texas.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Olateju Olajumoke A, Shrestha Mina, Altaie Alia, Varisco Tyler J, Thornton J Douglas
Аннотация
BACKGROUND: The state of Texas required state-licensed prescribers and pharmacies to query their patients' prescription histories in the state's prescription drug monitoring program (PDMP) before prescribing controlled substances, starting on March 1, 2020.
OBJECTIVES: To examine the effect of the PDMP mandate on the rate of queried prescriptions for opioids, benzodiazepines, barbiturates, and carisoprodol in Texas.
METHODS: Interrupted time-series analyses were conducted using monthly data from the Texas Prescription Monitoring Program (TPMP), covering September 1, 2019 till September 30, 2020. Changes in the rates of queried prescription trends 6 months before and after the implementation of the TPMP mandate were analyzed separately for each drug class. Separate analyses were conducted for prescriber- and pharmacy-related queries. Sensitivity analyses were performed by evaluating measures specific to the stimulant drug class (a drug class unaffected by the mandate) and extending the analysis to a 12-month postmandate period to assess longer term trends.
RESULTS: The mandate was associated with an immediate decline in the rate of prescription queries by prescribers across all drug classes (range: -10.7% to -4.8%) and an immediate increase in queries by pharmacies for all drug classes, except for barbiturates (0.2% to 11.5%). This resulted in an overall immediate decrease in prescription queries for barbiturates (-8.3%). Compared to the baseline (premandate), the change in overall monthly prescription queries across all drug classes showed an insignificant decline in both the main and sensitivity analyses.
CONCLUSION: The immediate impact of the TPMP may be limited, particularly given that the mandate's implementation coincided with the COVID-19 pandemic. To more effectively address controlled substance misuse, the state should consider strengthening the mandate and exploring additional measures to enhance its impact.
OBJECTIVES: To examine the effect of the PDMP mandate on the rate of queried prescriptions for opioids, benzodiazepines, barbiturates, and carisoprodol in Texas.
METHODS: Interrupted time-series analyses were conducted using monthly data from the Texas Prescription Monitoring Program (TPMP), covering September 1, 2019 till September 30, 2020. Changes in the rates of queried prescription trends 6 months before and after the implementation of the TPMP mandate were analyzed separately for each drug class. Separate analyses were conducted for prescriber- and pharmacy-related queries. Sensitivity analyses were performed by evaluating measures specific to the stimulant drug class (a drug class unaffected by the mandate) and extending the analysis to a 12-month postmandate period to assess longer term trends.
RESULTS: The mandate was associated with an immediate decline in the rate of prescription queries by prescribers across all drug classes (range: -10.7% to -4.8%) and an immediate increase in queries by pharmacies for all drug classes, except for barbiturates (0.2% to 11.5%). This resulted in an overall immediate decrease in prescription queries for barbiturates (-8.3%). Compared to the baseline (premandate), the change in overall monthly prescription queries across all drug classes showed an insignificant decline in both the main and sensitivity analyses.
CONCLUSION: The immediate impact of the TPMP may be limited, particularly given that the mandate's implementation coincided with the COVID-19 pandemic. To more effectively address controlled substance misuse, the state should consider strengthening the mandate and exploring additional measures to enhance its impact.